Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

Executive Summary

Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.


Related Content

Gilead Raises HCV Guidance Slightly, Still Mum On M&A
Deal Watch: Gilead And Spring Bank Set Second Trial Collaboration In HBV
Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Gilead's Bictegravir Data Could Mean Continued HIV Sector Dominance
Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
Gilead Gets CHMP Nod for New HIV Combo
CHMP Positive On Descovy, A Safer HIV Therapy?
With Parity Pricing, Gilead Relies On Genvoya Safety To Convert From Stribild
Gilead: Three HIV Launches Expected In Near-Term Future
Gilead's HIV franchise looks secure as 'son of Viread' impresses in PhIII


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts